ERBB2 and breast cancer: According to 2019 ASCO meeting presentations, it was reported that 70% of the breast cancer patients with HR+, HER2−, and N0 can forego chemotherapy when guided by recurrence score (https://ascopost.com/news/60141, accessed on 13 June 2019).